Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
NBP
$3.25
$
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Next Earnings
2026-02-25
Beta
1.617
Average Volume
Market Cap
Last Dividend
CIK
0001778016
ISIN
US44975P1030
CUSIP
44975P103
CEO
Xi-Yong Fu
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
32
IPO Date
2020-01-17
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform | ROCKVILLE, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines, today named Emmett T. Cunningham, Jr, MD, PhD, MPH, Co-Founder and Executive Chairman of Visara, Inc., as Vice Chairman of the NovaBridge Board of Directors (the Board). Dr. Cunningham will also join the Research and Development (R&D) Committee of the Board. | GlobeNewsWire | 2026-02-19 07:00:00 |
| NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer | ROCKVILLE, Md., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced enrollment of the first patient in the global Phase 2 randomized combination study evaluating givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative, 1L metastatic gastric cancer. Positive Phase 1b data position givastomig to be a potential best-in-class CLDN18.2-directed therapy for gastric cancer with a projected $12 billion market opportunity by 20301. Top line Phase 2 results are expected in 2027. | GlobeNewsWire | 2026-02-17 16:05:00 |
| NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei | ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company's ADSs in open market transactions. | GlobeNewsWire | 2026-01-20 07:00:00 |
| What's Going On With NovaBridge Stock Tuesday? | NovaBridge stock was trading higher Tuesday but has since reversed and begun trading lower. NovaBridge announced upgrade results from the Phase 1b combination study of givastomig. | Benzinga | 2026-01-06 12:14:16 |
| NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer | ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced positive updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative, first line (1L) metastatic gastric cancer. | GlobeNewsWire | 2026-01-06 07:00:00 |
| NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 | NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader | GlobeNewsWire | 2025-12-30 07:00:00 |
| NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO | ROCKVILLE, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced the presentation of new data from the expanded 3mg/kg every 6 week (Q6W) Phase 1 dosing study for ragistomig, a bispecific 4-1BB X PD-L1 antibody, in a poster at the European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025) by co-developer ABL Bio. The poster (Poster 257P), presented by Gerald Falchook, MD, Director of the Sarah Cannon Research Institute (SCRI) at HealthONE Denver, showed the new Q6W schedule demonstrated consistent monotherapy antitumor activity with improved immunological endpoints and tolerability. | GlobeNewsWire | 2025-12-10 16:30:00 |
| NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO | ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that new data from the expanded Phase 1 dosing study for ragistomig, a 4-1BB X PD-L1 bispecific antibody, will be presented in a poster at the European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025) by co-developer ABL Bio. The poster (Abstract #688) will be presented by Gerald Falchook, MD, Director of the Sarah Cannon Research Institute (SCRI) at HealthONE Denver, on Wednesday, December 10th at 5:30 PM GMT. | GlobeNewsWire | 2025-12-03 19:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-02-19 | 2026-02-19 | View Filing |
| 6-K | 2026-02-17 | 2026-02-17 | View Filing |
| 6-K/A | 2026-02-06 | 2026-02-06 | View Filing |
| 6-K | 2026-02-06 | 2026-02-06 | View Filing |
| SC 13D/A | 2026-02-03 | 2026-02-03 | View Filing |
| 6-K | 2026-01-22 | 2026-01-22 | View Filing |
| 6-K | 2026-01-22 | 2026-01-22 | View Filing |
| 6-K | 2026-01-16 | 2026-01-16 | View Filing |
| 6-K | 2026-01-06 | 2026-01-06 | View Filing |
| 6-K | 2025-12-18 | 2025-12-18 | View Filing |
| 6-K | 2025-12-10 | 2025-12-10 | View Filing |
| 6-K | 2025-12-04 | 2025-12-04 | View Filing |
| 6-K | 2025-10-31 | 2025-10-31 | View Filing |
| 6-K | 2025-10-30 | 2025-10-29 | View Filing |
| 424B3 | 2025-10-30 | 2025-10-29 | View Filing |
| 6-K | 2025-10-29 | 2025-10-29 | View Filing |
| 6-K | 2025-10-28 | 2025-10-28 | View Filing |
| 6-K | 2025-10-24 | 2025-10-24 | View Filing |
| 6-K | 2025-10-24 | 2025-10-24 | View Filing |
| 6-K/A | 2025-10-24 | 2025-10-24 | View Filing |
| 6-K | 2025-10-23 | 2025-10-23 | View Filing |
| 6-K | 2025-10-22 | 2025-10-22 | View Filing |
| 6-K | 2025-10-16 | 2025-10-16 | View Filing |
| 6-K | 2025-10-06 | 2025-10-06 | View Filing |
| 6-K | 2025-09-24 | 2025-09-24 | View Filing |
| S-8 | 2025-09-11 | 2025-09-11 | View Filing |
| 6-K | 2025-09-08 | 2025-09-08 | View Filing |
| 6-K | 2025-08-25 | 2025-08-25 | View Filing |
| 6-K | 2025-08-20 | 2025-08-20 | View Filing |
| 6-K | 2025-08-11 | 2025-08-11 | View Filing |
| SC 13D/A | 2025-08-07 | 2025-08-07 | View Filing |
| SC 13D | 2025-08-05 | 2025-08-05 | View Filing |
| 424B5 | 2025-08-04 | 2025-08-04 | View Filing |
| 6-K | 2025-08-04 | 2025-08-04 | View Filing |
| 6-K | 2025-08-01 | 2025-08-01 | View Filing |
| F-6EF | 2025-08-01 | 2025-08-01 | View Filing |
| 6-K | 2025-07-17 | 2025-07-17 | View Filing |
| 6-K | 2025-07-11 | 2025-07-11 | View Filing |
| 424B5 | 2025-07-11 | 2025-07-11 | View Filing |
| 6-K/A | 2025-07-11 | 2025-07-11 | View Filing |
| 6-K | 2025-07-02 | 2025-07-02 | View Filing |
| 6-K | 2025-06-26 | 2025-06-26 | View Filing |
| 6-K | 2025-06-12 | 2025-06-12 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-05-30 | 2025-05-30 | View Filing |
| EFFECT | 2025-05-16 | 2025-05-16 | View Filing |
| 6-K | 2025-05-15 | 2025-05-15 | View Filing |
| F-3 | 2025-05-02 | 2025-05-02 | View Filing |
| 6-K | 2025-04-30 | 2025-04-30 | View Filing |
| 6-K | 2025-04-04 | 2025-04-04 | View Filing |
| 6-K | 2025-04-03 | 2025-04-03 | View Filing |
| 20-F | 2025-04-03 | 2025-04-03 | View Filing |
| 6-K | 2025-03-21 | 2025-03-21 | View Filing |
| 6-K | 2025-03-07 | 2025-03-07 | View Filing |
| 6-K | 2025-02-27 | 2025-02-27 | View Filing |
| SC 13D | 2025-02-05 | 2025-02-05 | View Filing |
| 6-K | 2025-01-29 | 2025-01-29 | View Filing |
| 6-K | 2025-01-13 | 2025-01-13 | View Filing |
| 6-K | 2025-01-08 | 2025-01-08 | View Filing |
| 6-K | 2025-01-06 | 2025-01-06 | View Filing |
| 6-K | 2024-12-03 | 2024-12-03 | View Filing |
| 6-K | 2024-11-14 | 2024-11-14 | View Filing |
| 6-K | 2024-11-06 | 2024-11-06 | View Filing |
| 6-K | 2024-11-05 | 2024-11-05 | View Filing |
| 6-K | 2024-10-24 | 2024-10-24 | View Filing |
| 6-K | 2024-09-23 | 2024-09-23 | View Filing |
| 6-K | 2024-09-16 | 2024-09-16 | View Filing |
| 6-K | 2024-08-30 | 2024-08-30 | View Filing |
| 6-K | 2024-08-28 | 2024-08-28 | View Filing |
| 6-K | 2024-08-07 | 2024-08-07 | View Filing |
| 6-K | 2024-07-15 | 2024-07-15 | View Filing |
| 6-K | 2024-06-06 | 2024-06-06 | View Filing |
| 6-K | 2024-06-05 | 2024-06-05 | View Filing |
| S-8 | 2024-05-30 | 2024-05-30 | View Filing |
| 6-K | 2024-05-23 | 2024-05-23 | View Filing |
| 20-F | 2024-04-30 | 2024-04-30 | View Filing |
| 6-K | 2024-04-15 | 2024-04-15 | View Filing |
| 6-K | 2024-04-02 | 2024-04-02 | View Filing |
| 6-K | 2024-04-01 | 2024-04-01 | View Filing |
| 6-K | 2024-03-15 | 2024-03-15 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|